RxDoctor Payments Data

Ronald Gall, MD

Internal Medicine · Cincinnati, OHNPI 1952338550

Payments from drug & device makers

$7,695in general payments, 2019–2025

Across 555 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$884
  • Pfizer$702
  • AstraZeneca$583
  • GSK$562
  • Lilly USA, LLC$479
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,669100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,695 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$108,204
Medicare patients
353
Services billed
1,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$127,552
FarxigaDapagliflozin Propanediol122$120,869
EliquisApixaban120$87,256
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$64,991
XareltoRivaroxaban48$63,884
JardianceEmpagliflozin48$61,693
JanuviaSitagliptin Phosphate16$25,398
TrulicityDulaglutide23$23,929
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$22,563
MyrbetriqMirabegron20$15,079
Tresiba Flextouch U-200Insulin Degludec18$14,988
Tresiba Flextouch U-100Insulin Degludec15$8,631
AmbienZolpidem Tartrate13$7,610
Atorvastatin Calcium1,047$7,268
Omeprazole404$4,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$583$146,977173 claims
Novo NordiskOzempic$1,528$127,552112 claims
PfizerEliquis$702$87,256120 claims
GSKTrelegy Ellipta$562$64,99184 claims
Johnson & JohnsonXarelto$343$63,88448 claims
Boehringer IngelheimJardiance$321$61,69348 claims
Lilly USA, LLCTrulicity, Humalog Mix 75-25$479$25,71234 claims
MerckJanuvia$188$25,39816 claims
Astellas Pharma US IncMyrbetriq$47$15,07920 claims
Sanofi-aventis U.S. LLCAmbien$48$7,61013 claims
AbbVieSynthroid$884$2,69495 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →